Catalyst Pharmaceuticals (CPRX) Receives News Sentiment Rating of 0.12

Press coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.8689780917613 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

• Global Blood Therapeutics Inc. (GBT) is at $27.10 per share and Catalyst Pharmaceuticals, Inc. (CPRX) is listed at $2.75 – Stocks Gallery (stocksgallery.com)
• Catalyst Pharmaceuticals Inc (CPRX) Shares Dip Below Balance Step – Stock Press Daily (stockpressdaily.com)
• Vince Holding Corp (VNCE) and Catalyst Pharmaceuticals Inc (CPRX) Shares Needle Moving On Volume – FLBC News (flbcnews.com)
• WisdomTree US Quality Dividend Growth Fund (DGRW) and Catalyst Pharmaceuticals Inc (CPRX) Seeing Increased … – FLBC News (flbcnews.com)
• Popping up on Watch-lists are Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares – FLBC News (flbcnews.com)

CPRX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research report on Monday, May 22nd. Piper Jaffray Companies set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 7th. Finally, Roth Capital set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 10th.

Shares of Catalyst Pharmaceuticals (CPRX) opened at 2.78 on Friday. Catalyst Pharmaceuticals has a 52 week low of $0.88 and a 52 week high of $3.20. The stock’s market capitalization is $235.06 million. The stock has a 50 day moving average of $2.88 and a 200-day moving average of $2.10.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, equities research analysts expect that Catalyst Pharmaceuticals will post ($0.23) EPS for the current year.

WARNING: This piece was reported by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at [[permalink]].

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.